Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 12;187(25):7248-7266.e34.
doi: 10.1016/j.cell.2024.09.032. Epub 2024 Oct 16.

IRE1α silences dsRNA to prevent taxane-induced pyroptosis in triple-negative breast cancer

Affiliations

IRE1α silences dsRNA to prevent taxane-induced pyroptosis in triple-negative breast cancer

Longyong Xu et al. Cell. .

Abstract

Chemotherapy is often combined with immune checkpoint inhibitor (ICIs) to enhance immunotherapy responses. Despite the approval of chemo-immunotherapy in multiple human cancers, many immunologically cold tumors remain unresponsive. The mechanisms determining the immunogenicity of chemotherapy are elusive. Here, we identify the ER stress sensor IRE1α as a critical checkpoint that restricts the immunostimulatory effects of taxane chemotherapy and prevents the innate immune recognition of immunologically cold triple-negative breast cancer (TNBC). IRE1α RNase silences taxane-induced double-stranded RNA (dsRNA) through regulated IRE1-dependent decay (RIDD) to prevent NLRP3 inflammasome-dependent pyroptosis. Inhibition of IRE1α in Trp53-/- TNBC allows taxane to induce extensive dsRNAs that are sensed by ZBP1, which in turn activates NLRP3-GSDMD-mediated pyroptosis. Consequently, IRE1α RNase inhibitor plus taxane converts PD-L1-negative, ICI-unresponsive TNBC tumors into PD-L1high immunogenic tumors that are hyper-sensitive to ICI. We reveal IRE1α as a cancer cell defense mechanism that prevents taxane-induced danger signal accumulation and pyroptotic cell death.

Keywords: ER stress; IRE1α; PD-L1-negative breast cancer; dsRNA; pyroptosis.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests M.F.R. receives research funding from Pfizer and Genentech and consulting fees from Novartis, Seagen, Macrogenics, and AstraZeneca. M.F.R. is the PI of clinical trial NCT03950570. X.C. reports previous research funding from Fosun Pharma. M.J.E. holds patents and receives income from Veracyte on the PAM50-based products, Prosigna.

References

    1. Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, Liu J, Subudhi SK, Poon C, Gant KL, et al. (2023). Immune checkpoint therapy-current perspectives and future directions. Cell 186, 1652–1669. 10.1016/j.cell.2023.03.006. - DOI - PubMed
    1. Iwai Y, Terawaki S, and Honjo T. (2005). PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int Immunol 17, 133–144. 10.1093/intimm/dxh194. - DOI - PubMed
    1. Leach DR, Krummel MF, and Allison JP (1996). Enhancement of Antitumor Immunity by CTLA-4 Blockade. Science 271, 1734–1736. 10.1126/science.271.5256.1734. - DOI - PubMed
    1. Ribas A, and Wolchok JD (2018). Cancer immunotherapy using checkpoint blockade. Science 359, 1350–1355. 10.1126/science.aar4060. - DOI - PMC - PubMed
    1. Hegde PS, and Chen DS (2020). Top 10 Challenges in Cancer Immunotherapy. Immunity 52, 17–35. 10.1016/j.immuni.2019.12.011. - DOI - PubMed

MeSH terms

LinkOut - more resources